Furthermore, low-molecular compounds, such as Hes1 dimer inhibitors for neural stem cell (NSC) differentiation [84] and histone deacetylase 3 (HDAC3) inhibitors [85] and SIRT2 inhibitors [86] for neurodegenerative diseases (Figure 15), can be used in combination with immunotherapy. Here, HES1 is linked to neurodegenerative disease.